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ScienceDirectIn the last decade, progress in the analysis of the human
immune response and in the isolation of human monoclonal
antibodies have provided an innovative approach to the
identification of protective antigens which are the basis for the
design of vaccines capable of eliciting effective B-cell
immunity. In this review we illustrate, with relevant examples,
the power of this approach that can rapidly lead to the
identification of protective antigens in complex pathogens,
such as human cytomegalovirus and Plasmodium falciparum,
and of conserved sites in highly variable antigens, such as
influenza hemagglutinin and HIV-1 Env. We will also discuss
how the genealogical analysis of antigen-stimulated B cell
clones provides the basis to delineate the best suitable prime-
boost vaccination strategy for the induction of broadly
neutralizing antibodies.
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Introduction
When our immune system is challenged by an infectious
agent, a polyclonal antibody response is generated against
multiple protein and non-protein antigens. The extent of
the response reflects the immunogenicity of the individ-
ual components, which is determined by multiple factors
such as their abundance, their complexity and their
capacity to bind to cellular receptor and trigger innate
immunity, not to mention the influence of pre-existing
immunity. In general, only a fraction of the antibodies
produced exerts protective activity by binding toCurrent Opinion in Immunology 2016, 41:62–67 molecules that are required for invasion or virulence or
by eliciting effector mechanisms. For instance, the largest
fraction of antibodies produced in response to a virus
infection is directed against internal or surface proteins in
a denatured or post-fusion conformation and is therefore
devoid of neutralizing activity [1,2,3]. Thus, the immu-
nogenicity of the most abundant proteins offers to the
pathogen the opportunity to limit the most effective
response by a mechanism of antigenic competition.
In this review we discuss how recent advances in the
characterization of the neutralizing antibody response to
human pathogens, combined with advanced protein en-
gineering methods, have provided a new way to solve the
problem of antigenic competition and have led to the
production of vaccine candidates that elicit antibody
responses of high magnitude and specific activity.
Analytic vaccinology: the cases of HCMV and
malaria
Human cytomegalovirus (HCMV) is a herpes virus that
establishes a lifelong infection in healthy individuals, but
causes serious pathology in the fetus and in immunosup-
pressed patients and has been associated with immune
senescence and atherosclerosis [4]. HCMV uses multiple
glycoprotein complexes for binding and fusion to host cells
and has a broad cell tropism, being able to infect fibroblasts
as well as epithelial, endothelial and myeloid cells [5]. The
fusion protein gB has been considered the most obvious
vaccine candidate but clinical trials with recombinant gB
(in the post-fusion conformation) has shown limited effi-
cacy [6]. To identify the most potent HCMV vaccine, an
analytic vaccinology approach was used to isolate, from
memory B cells of naturally infected donors, a large panel
of monoclonal antibodies selected for their capacity to
neutralize HCMV infection of multiple cell types [7]
(Figure 1). This approach led to the identification of a
new class of antibodies that were 1000 fold more potent
that antibodies to gB in neutralizing HCMV infection of
epithelial, endothelial and myeloid cells. These antibodies
were mapped to nine distinct sites on the gH/gL/UL128-
131A complex, a pentameric complex that was previously
found to be required for infection of those cell types [8].
The identification of the pentamer as the target of the most
potent antibodies was subsequently confirmed by several
studies [9,10,11]. As an example, a soluble pentamer
produced by stably a transfected CHO cell line elicited in
mice antibody titers that persisted to high levels over timewww.sciencedirect.com
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Antibody-guided vaccine design. Human monoclonal antibodies isolated from immune donors are used to identify protective antigens and
epitopes. The antigens discovered from complex pathogens are produced as recombinant proteins (path 1; e.g. HCMV pentamer) and, when
necessary, engineered for increased stability (path 2; e.g. stabilized pre-fusion HRSV F protein) or modified to express particular domains or
epitopes (path 3; e.g. head-less HA or Palivizumab epitope displayed on VLPs).and that were 300-1000 fold higher than those found in
individuals that recovered from primary HCMV infection
[10]. Importantly, the antibodies elicited by the penta-
mer vaccine prevented cell-to-cell spread and viral dis-
semination from endothelial cells to leukocytes and
neutralized infection of both epithelial cells and fibroblasts
due to the production of antibodies to the gH glycoprotein,
which is required for fibroblasts infection.www.sciencedirect.com The target-agnostic approach can be particularly useful to
identify targets in complex pathogens such as bacteria
and parasites. An interesting example regards the identi-
fication of variant surface antigens (VSAs) which are
present on the surface of Plasmodium falciparum (Pf)-
infected erythrocytes and mediate adhesion to endothe-
lia, leading to pathology. The VSAs are encoded by more
that 200 genes that are polymorphic and clonallyCurrent Opinion in Immunology 2016, 41:62–67
64 Vaccinesexpressed, thus providing the pathogen with a powerful
mechanism of escape from the antibody response. Human
monoclonal antibodies isolated from multiparous women
have been used to identify VAR2CSA as the primary
target of antibodies that protect from placental malaria
[12]. In a more recent study, Tan et al. isolated several
antibodies that broadly react with erythrocytes infected
with different Pf isolates and identified the target anti-
gens as distinct RIFINs [13]. Surprisingly, these anti-
bodies acquired their broad reactivity through a novel
mechanism of insertion of a large DNA fragment between
the V and DJ segments. The insert originates from
chromosome 19 and encodes the extracellular domain
of the collagen-binding inhibitory receptor LAIR-1,
which is both necessary and sufficient for binding to
RIFINs. Importantly, the LAIR-1 domain carries somatic
mutations that abolish binding to collagen and increase
binding to infected erythrocytes. These findings illus-
trate, with a biologically relevant example, a novel mech-
anism of antibody diversification and demonstrate the
existence of conserved epitopes as candidates for the
development of a malaria vaccine [14].
Structure-based vaccinology: the case of
HRSV
Human respiratory syncytial virus (HRSV) is the most
prominent viral agent of pediatric respiratory infections.
Currently, the only treatment available is Palivizumab
[15], a humanized monoclonal antibody that binds to an
epitope that is conserved in the pre-fusion and post-
fusion conformation of the HRSV F protein [16]. On
the basis of the properties of Palivizumab, the initial
efforts towards an HRSV vaccine were focused on the
use of the post-fusion F-protein that was engineered
to increase its solubility, resulting into highly stable
immunogen forms, that were tested either as soluble
antigens or displayed onto virus-like particles (VLPs)
[17,18].
Two recent studies used the structural information on the
Palivizumab linear epitope, a 24 amino acid helix–loop–
helix structure, to develop epitope-focused vaccines.
Correia et al. used computational protein design to gen-
erate stable protein scaffolds that accurately mimic the
Palivizumab epitope and, when chemically linked to
VLPs, induce HRSV-neutralizing antibodies in macaques
[19]. In a subsequent study, Milich and coworkers used
an empirical approach by directly inserting the Palivizu-
mab epitope in VLPs composed of woodchuck hepadna-
virus core (WHcAg) protein, which were then selected
with the antibody and found to be immunogenic in
rodents [20]. While these studies provide for the first
time a proof-of-principle for epitope-focused vaccinology
(Figure 1), it is not evident what could be the advantage
of limiting the response to a single epitope, given the
presence of several conserved epitopes in the HRSV F
protein.Current Opinion in Immunology 2016, 41:62–67 The analysis of the human antibody response to HRSV
[21,22] and the isolation of human neutralizing monoclo-
nal antibodies [23,24] showed that the large majority of
HRSV neutralizing antibodies elicited by natural infection
are specific for the pre-fusion F protein conformation and,
unlike Palivizumab, do not cross-react with the post-fusion
conformation. On the basis of these observations and on
the crystal structure of the pre-fusion F protein in complex
with a neutralizing antibody [25], Kwong and coworkers
used structure-based design to produce a stabilized HRSV
F protein through the introduction of cysteine residues
and the filling of hydrophobic cavities [26,27]. This
protein (dubbed DS-Cav1) maintained binding to potent
neutralizing antibodies and was able to elicit in mice and
macaques levels of HRSV-neutralizing antibodies that
exceeded the protective threshold. These results provide
a clear example of structure-driven vaccinology to gener-
ate stable immunogens capable of inducing a polyclonal
response to multiple neutralizing epitopes of viral fusion
proteins, overcoming the problem of their intrinsic insta-
bility (Figure 1).
Epitope-focused vaccinology: the cases of
influenza A
Influenza A and HIV-1 are the prototypes of viruses that
evade the antibody response by continuously mutating
surface glycoproteins. However, certain sites are relative-
ly conserved since they are required for infectivity and
fusion and can be therefore exploited to design vaccines
capable of inducing broad protection. In the last decade
the isolation of broadly neutralizing antibodies has pro-
vided a powerful platform to identify such epitopes, thus
speeding up vaccine design efforts [28,29].
The sialic acid binding pocket of influenza hemagglutinin
(HA) is a conserved site that can be targeted by anti-
bodies, such as CH65, that carry at the tip of HCDR3 a
distinct motif that mimics sialic acid [30]. Importantly,
these antibodies arise from diverse germline origins and
affinity maturation pathways, suggesting that such an
antibody response could be rapidly generated by appro-
priate immunogens. However, the breadth of these anti-
bodies is somewhat limited due to the presence of highly
variable residues that flank the receptor binding site.
The HA stem is a more conserved region which has been
shown to be recognized by different families of broadly
neutralizing antibodies that recognize multiple subtypes
in group 1 [31–34], group 2 [35] and, in some cases, both
group 1 and group 2 influenza A viruses [36,37,38].
Recently, Pappas et al. showed that most individuals
make antibodies that broadly recognize group 1 subtypes.
This public antibody response relies exclusively on the H
chain, which is encoded by VH1-69 alleles with phenyl-
alanine at position 54 and a short HCDR3 with tyrosine at
position 98. Interestingly, through the reconstruction of
the developmental pathways of several such clones, it waswww.sciencedirect.com
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cases by a single mutation [39]. These findings explain
the high frequency of antibodies specific for the stem of
group 1 HAs. In contrast, antibodies that recognize both
group 1 and group 2 HAs are much less frequent since
they use different VH/VL genes. Furthermore they are
generated through a complex developmental pathway,
being first selected for their germ-line reactivity against
group 1 and subsequently acquiring group 2 reactivity
through somatic mutations [36]. The latter finding sug-
gests that the rare pan-influenza A neutralizing antibodies
might be elicited using an appropriate heterologous
prime-boost strategy.
The identification of the HA stem as a conserved site of
influenza HA has raised the possibility of developing a
universal influenza vaccine [40]. Two approaches have
been developed towards this ambitious goal. The first
involves a prime-boost strategy using chimeric HA mole-
cules carrying the same stem combined with heterolo-
gous heads [41,42] and is based on the classical principle
of the original antigenic sin that represents in this case a
natural mechanism of immunofocusing. The second
approach of epitope-focused vaccinology involves the
production of headless HAs [43] (Figure 1). In a recent
report, Yassine et al. used iterative cycles of structure-
based design to produce a stabilized  stem immunogen,
HA-SS, genetically fused to ferritin nanoparticles, which
is recognized by stem-specific monoclonal antibodies
and elicits, in mice and ferrets, broadly cross-reactive
antibodies [44]. In general, the assemblies of multiple
copies of subunit antigens in well-ordered arrays, such as
in the case of ferritin or VLPs, offer the advantage of
mimicking the repetitiveness of most natural pathogens
surface proteins potentially providing improved antigen
stability and immunogenicity [45,46]. In an another
study, Impagliazzo et al. used a rational design combined
with a library approach to generate a HA stem antigen
called mini-HA that protects mice and non-human pri-
mates from lethality and symptoms [47]. It should be
noted that in both studies the neutralizing antibody
levels induce by the vaccine were modest, suggesting
that in vivo protection may be achieved through a com-
bination of neutralization and Fc-dependent effector
function, which is known to be elicited by anti-stem
antibodies [36,48,49]. The headless HA vaccine has
been shown to work for group 1 influenza viruses and
should be extended to group 2 viruses, and possibly to
influenza B, in order to fully realize the dream of a
universal influenza vaccine.
Factors that limit the antibody response: the
challenge of HIV-1
An effective antibody response is limited by the frequen-
cy of antigen-specific B cells in the naı¨ve repertoire, by
the number of mutations required to reach high affinity or
breadth, and by the availability of T cell help. Thus, anwww.sciencedirect.com ideal vaccine should contain a sufficiently high number of
T and B cell epitopes and should be formulated to
effectively prime the germinal center reaction [50]. In
addition, the finding that preexisting immunity can shape
the antibody response to new structurally related antigens
[51–53] suggests modalities of prime-boost immunization
to optimize the antibody response [54].
Recent technological advances are increasingly used to
investigate the developmental pathways leading to po-
tent and broadly neutralizing antibodies. These include
the in depth analysis of the antibody response through the
isolation of multiple cells within the same lineage, possi-
bly implemented by next generation sequencing and
deconvolution of the serum antibody repertoire through
LC–MS/MS analysis [39,55,56]. The systematic recon-
struction of the genealogy trees of antibody lineages has
shown that neutralizing antibodies to influenza or HRSV
mature rapidly [39] or may not even need affinity
maturation, while somatic mutations are critical to
achieve breadth [23,36]. The situation is strikingly dif-
ferent in the case of HIV-1, where viruses and B cells co-
evolve over a period of years, leading to a slow and
infrequent development of broadly neutralizing antibo-
dies [57]. In the last decade many new broadly neutraliz-
ing antibodies of high potency have been isolated and
new sites of vulnerability on the Env protein have been
defined. Importantly, in the last few years cryo-EM and
crystallography were used to finally solve the structure of
a stabilized soluble Env trimer molecule (i.e. BG505
SOSIP), alone or in combination with several broadly
neutralizing antibodies [58–60]. These constructs are now
considered a relevant mimic of the native functional
trimer being recognized preferentially by neutralizing
antibodies. The HIV-1 broadly neutralizing antibodies
are found only in a fraction of infected individual and
have a slow and complex developmental pathway or
derive from very rare precursors characterized by ex-
tremely long HCDR3. These observations have led to
the proposal of a prime-boost strategy with different
antigens that target the naı¨ve precursors and different
stages of the antibody developmental pathway defined as
‘B cell-lineage vaccine design’ [61].
These hurdles represent a significant challenge to the
development of an effective HIV-1 vaccine. However,
these efforts contributed to the development of novel
vaccine design strategies that represent a fertile ground
for significant advances in the generation of new and
better vaccines against other pathogens.
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